Supplementary Materials

Supplementary Material for:

Plasma AR and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, Anuradha Jayaram, Nicola Casiraghi, Daniel Wetterskog, Samanta Salvi, Dino Amadori, Zafeiris Zafeiriou, Pasquale Rescigno, Diletta Bianchini, Giorgia Gurioli, Valentina Casadio, Suzanne Carreira, Jane Goodall, Anna Wingate, Roberta Ferraldeschi, Nina Tunariu, Penny Flohr, Ugo De Giorgi, Johann S. de Bono, Francesca Demichelis,* Gerhardt Attard*

*Corresponding author. E-mail: demichelis{at}science.unitn.it (F.D.); gerhardt.attard{at}icr.ac.uk (G.A.)

Published 4 November 2015, Sci. Transl. Med. 7, 312re10 (2015)
DOI: 10.1126/scitranslmed.aac9511

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Circulating tumor DNA fraction at response compared to after-disease progression.
  • Fig. S2. Validation of next-generation sequencing calls of AR gain.
  • Fig. S3. Total cell-free DNA concentration versus tumor DNA fraction.
  • Fig. S4. Overall and progression-free survival analysis of circulating tumor DNA fraction.
  • Fig. S5. Validation of AR mutations.
  • Fig. S6. PSA change waterfall plot for tumor DNA fraction.
  • Fig. S7. Overall and progression-free survival analysis of AR normal versus AR gain.
  • Fig. S8. Swimmer plot of patients with a PSA decline.
  • Fig. S9. Sensitivity analysis of aberrant tumor read percentage estimation.
  • Fig. S10. Specificity analysis of aberrant tumor read percentage estimation and local tumor content (LTC) median false-positive analysis.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Coverage statistics summary (provided as an Excel file).
  • Table S2. Content of the custom AmpliSeq panel IAD44450_30 (provided as an Excel file).
  • Table S3. Tumor content (TC) of study samples (provided as an Excel file).
  • Table S4. AR gene copy number call data (provided as an Excel file).
  • Table S5. Somatic point mutation data (GRCh37/hg19) (provided as an Excel file).
  • Table S6. Survival data for patients with L702H or T878A AR mutations (provided as an Excel file).
  • Table S7. Multivariate analyses (provided as an Excel file).
  • Table S8. Germline sample sequencing statistics (provided as an Excel file).

[Download Tables S1 to S8]